Ryvu Therapeutics S.A. (WSE: RVU)
Health Care · Life Sciences Tools & Services · PL
zł17.14
+3.88% today · -37.0% 1Y
Ryvu Therapeutics S.A. (WSE: RVU) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $97.37M and employs 228 people.
Over the last twelve months the share price has lost 37.0%, trading between 13.64 and 31.90.
Tweenvest scores Ryvu Therapeutics S.A. across four factors: quality 37/100, value 50/100, growth 45/100. Its strongest factor is value.
RVU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $97.37M
- Revenue (TTM)
- $22.31M
- P/E
- —
- EPS
- -2.98
- Dividend yield
- —
- Beta (5Y)
- 0.41
- 52-week high
- zł31.90
- 52-week low
- zł13.64
- Avg volume (3M)
- —
- Shares outstanding
- 23.12M
- Employees
- 228
- Next earnings
- —
About Ryvu Therapeutics S.A.
Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing novel small molecule treatments for oncology. Their primary experimental drug, RVU120, functions as a CDK8 kinase inhibitor and shows promise for development across hematological malignancies and solid tumors. This compound is presently in a Phase 1b clinical study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Among their other assets is SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, which is currently undergoing a Phase 2 clinical trial for acute myeloid leukemia. Furthermore, Ryvu's earlier research pipeline explores candidates in areas such as kinases, cancer metabolism, synthetic lethality, and immuno-oncology. The company, established in 2007, is based in Kraków, Poland.
- ISIN
- PLSELVT00013
- Founded
- 2007
- Listed since
- Jul 14, 2011
- Exchange
- Warsaw Stock Exchange
- Currency
- PLN
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eurofins-Cerep SAENXTPA: ALECR | $102.22M | €18,100.00 | +19.87% |
| Selvita S.A.WSE: SLV | $99.32M | zł21.00 | -0.94% |
| Borosil Scientific LimitedBSE: 544184 | $98.61M | Rs107.30 | -4.41% |
| Macrogen, Inc.KOSDAQ: A038290 | $98.22M | ₩12,180.00 | -3.26% |
| Celemics, Inc.KOSDAQ: A331920 | $90.08M | ₩10,830.00 | +1.50% |
| HLB bioStep Co.,Ltd.KOSDAQ: A278650 | $80.75M | ₩6,310.00 | +119.48% |
| Nanoform Finland OyjHLSE: NANOFH | $74.13M | €0.76 | -1.55% |
| HeXun Biosciences Co., Ltd.TPEX: 6986 | $72.23M | NT$44.30 | +0.68% |
Figures last refreshed Oct 11, 2026.